Navigation Links
Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
Date:11/18/2009

SAN DIEGO, Nov. 18 /PRNewswire-FirstCall/ -- Entest BioMedical Inc. (OTC Bulletin Board: ENTB) announced today the filing of a third patent application relating to the area of chronic obstructive pulmonary disease (COPD), a condition that affects more than 5 million patients in the United States, resulting in more than 120,000 deaths per year. The application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation.

"The importance of the inflammatory process in COPD is exemplified by the use of broad-acting steroids that reduce inflammation. Unfortunately, these drugs do not address the cause of the inflammation, and have a variety of adverse effects," stated Dr. Stephen Josephs, inventor of the technology.

A recent article "Immunologic aspects of chronic obstructive pulmonary disease" by Cosio et al in the June 4th, 2009 issue of New England Medical Journal suggests that COPD may actually be not just a disease of inflammation but, of active immunological attack. The current technology seeks to induce a process in which immunity towards components of the body is blocked.

"To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy. The current patent application has a variety of derivative uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry," stated David Koos, Entest's CEO.

The essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes. Instead of us "telling the body" what it should do with a blunt-force approach, as is the standard of care, the current invention uses more natural and slow acting interventions.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTC Bulletin Board: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

    Contact:

    David R. Koos, Chairman & CEO
    619.702.1404 Direct
    619.330.2328 Fax

    Entest BioMedical Inc.
    info@EntestBio.com
    www.EntestBio.com

SOURCE Entest BioMedical Inc.


'/>"/>
SOURCE Entest BioMedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Adipose-derived Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Groups, Entest BioMedical Inc. Researcher
2. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
3. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
4. 40 Years on the Leading Edge: Case Western Reserve Universitys Biomedical Engineering Department Commemorates Achievement, Looks to Future
5. Healthnostics Unveils Biomedical Content Strategy for Medbioworld.com
6. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
7. Biomedical Research Organization Launches Groundbreaking National TV Campaign
8. Nova Biomedical and CCS Medical Reach Definitive Agreement for a Subsidiary of Nova Biomedical to Acquire Assets of CCS Medicals Subsidiary, Sanvita Inc.
9. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
10. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
11. ETC Biomedical Announces Chamber Sale in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Looking for a ... Diego’s premiere hands-on cooking experience. Offering everything from gourmet cooking classes to weekend ... won’t forget. , Guests that visit LaJollaCooks4u share an experience unlike any other. ...
(Date:5/4/2016)... , ... May 04, 2016 , ... PBI-Gordon Corporation is ... Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, after ... a wide variety of roles, ranging from customer service to national product manager, to ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs ... on May 31st and June 1st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/3/2016)... , May 3, 2016  Dr. Thomas ... surgeon in The Woodlands, Texas , ... 24 percent of treated fat cells in just 25-minutes, ... Close to 90 percent of Americans report feeling bothered ... Nonsurgical fat reduction procedures are a growing industry. This ...
Breaking Biology Technology:
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/3/2016)... Calif. , March 3, 2016  FlexTech, a ... the categories of Innovation, Research & Development, Leadership in ... Leadership. This is the 9 th year of ... group of companies and individuals from past years ... based on a pre-described set of criteria, by a ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
Breaking Biology News(10 mins):